Transcriptional repressors of E-cadherin in metastasis
Project Number5F32CA112989-03
Contact PI/Project LeaderFREEMAN, KEVIN W
Awardee OrganizationHARVARD MEDICAL SCHOOL
Description
Abstract Text
DESCRIPTION (provided by applicant): Aggressive carcinomas are characterized by epithelial to mesenchymal transition (EMT). The hallmarks of EMT, loss of cell-cell interactions and an increase in cell motility, potentiate the exodus of cancer cells from the primary tumor site, increasing the likelihood of metastasis. In a number of epithelial cell lines continuous tumor growth factor beta 1 (TGF-beta1) signaling is necessary for initiating and maintaining EMT. Multiple TGF-beta1 induced transcriptional repressors (TITR) of E-cadherin have been implicated in EMT, including Snail, Slug, ZEB-1 and ZEB-2. We will test the hypothesis that a cell's commitment to EMT may be determined by positive and negative feedback loops involving the TITRs by using dominant negative versions of the TITRs, small interfering RNA (siRNA) directed towards the TITRs and overexpression of the individual TITRs in EpH4 cells. To firmly establish the role of these TITRs in EMT mediated metastasis, we will determine in vivo if the TITRs cause increased metastatic potential of EpH4 cells. Finally using a newly established genome wide screen based on siRNA we will identify shared downstream signaling factors of TGF-beta1 that control the expression of the TITRs, providing therapeutic targets for preventing metastasis.
No Sub Projects information available for 5F32CA112989-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F32CA112989-03
Patents
No Patents information available for 5F32CA112989-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F32CA112989-03
Clinical Studies
No Clinical Studies information available for 5F32CA112989-03
News and More
Related News Releases
No news release information available for 5F32CA112989-03
History
No Historical information available for 5F32CA112989-03
Similar Projects
No Similar Projects information available for 5F32CA112989-03